Nirsevimab Reduced Infant Antibiotic Use

A study found that nirsevimab led to significant decreases in antibiotic prescriptions for infants.

Updated on Sept. 18, 2026 in Asthma

Bold vector editorial illustration of a glass medical ampoule, representing infant health and disease prevention. — A study found that the RSV vaccine nirsevimab significantly decreased antibiotic prescriptions in infants by preventing initial respiratory viral infections. AI Illustration. Upload story photo >

Live Poll

Do you believe preventative infant treatments are an effective way to lower future antibiotic use?

Between 2023 and 2025, infants who received nirsevimab showed a 14.4% reduction in antibiotic prescriptions for outpatient acute respiratory tract infections. The treatment also successfully lowered RSV-related hospitalizations by 69.4% among the study population.

Why it matters

Nirsevimab prevents upstream viral infections, which in turn reduces the secondary bacterial infections that typically necessitate the use of antibiotics in young infants.

The study of 15,341 infants tracked antibiotic prescriptions over two respiratory seasons, noting a 40.3% reduction in prescriptions for bronchiolitis and a 26.8% reduction for acute otitis media.

The players

Children's Hospital of Philadelphia

This pediatric healthcare institution served as the primary site for the study clinics and research data collection.

The details

Researchers at the Children's Hospital of Philadelphia compared health outcomes between infants who received nirsevimab and those who did not over a six-month period following primary care visits. By preventing initial viral respiratory infections, the treatment significantly lowered the downstream need for antibiotics to treat secondary complications.

2023 marked the debut of nirsevimab.
The study spanned the 2023-2025 respiratory virus seasons.

The Big Picture

This research follows the established patterns set by the Children's Hospital of Philadelphia pediatric research protocols. It confirms the efficacy of preventative interventions in reducing secondary medical requirements.

Parents may see a reduction in the need for antibiotic courses for their infants when utilizing nirsevimab for RSV prevention. This shift potentially simplifies early childhood treatment plans and reduces exposure to unnecessary medications.

The takeaway

Preventative viral treatments like nirsevimab provide a dual benefit by reducing both severe hospitalization risk and the reliance on antibiotics. Families should consult with their pediatricians to discuss how this preventative measure fits into an infant's overall health strategy.